Molecular markers in bladder cancer

Francesco Soria, Laura Maria Krabbe, Tilman Todenhöfer, Jakub Dobruch, Anirban P. Mitra, Brant A. Inman, Kilian M. Gust, Yair Lotan, Shahrokh F. Shariat

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: Use of molecular markers in urine, tissue or blood offers potential opportunities to improve understanding of bladder cancer biology which may help identify disease earlier, risk stratify patients, improve prediction of outcomes or help target therapy. Methods: A review of the published literature was performed, without restriction of time. Results: Despite the fast-growing literature about the topic and the approval of several urinary biomarkers for use in clinical practice, they have not reached the level of evidence for widespread utilization. Biomarkers could be used in different clinical scenarios, mainly to overcome the limitations of current diagnostic, predictive, and prognostic tools. They have been evaluated to detect bladder cancer in asymptomatic populations or those with hematuria and in surveillance of disease as adjuncts to cystoscopy. There is also a potential role as prognosticators of disease recurrence, progression and survival both in patients with non-invasive cancers and in those with advanced disease. Finally, they promise to be helpful in predicting the response to local and/or systemic chemotherapy and/or immunotherapy. Conclusions: To date, due to the lack of high-quality prospective trials, the level of evidence provided by the current literature remains low and, therefore, the potential of biomarkers exceeds utilization in clinical practice.

Original languageEnglish (US)
JournalWorld Journal of Urology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Urinary Bladder Neoplasms
Biomarkers
Cystoscopy
Hematuria
Immunotherapy
Disease Progression
Urine
Recurrence
Drug Therapy
Survival
Population
Neoplasms
Therapeutics

Keywords

  • Bladder cancer
  • Blood biomarkers
  • Guidelines
  • Tissue biomarkers
  • Urinary biomarkers

ASJC Scopus subject areas

  • Urology

Cite this

Soria, F., Krabbe, L. M., Todenhöfer, T., Dobruch, J., Mitra, A. P., Inman, B. A., ... Shariat, S. F. (Accepted/In press). Molecular markers in bladder cancer. World Journal of Urology. https://doi.org/10.1007/s00345-018-2503-4

Molecular markers in bladder cancer. / Soria, Francesco; Krabbe, Laura Maria; Todenhöfer, Tilman; Dobruch, Jakub; Mitra, Anirban P.; Inman, Brant A.; Gust, Kilian M.; Lotan, Yair; Shariat, Shahrokh F.

In: World Journal of Urology, 01.01.2018.

Research output: Contribution to journalArticle

Soria, F, Krabbe, LM, Todenhöfer, T, Dobruch, J, Mitra, AP, Inman, BA, Gust, KM, Lotan, Y & Shariat, SF 2018, 'Molecular markers in bladder cancer', World Journal of Urology. https://doi.org/10.1007/s00345-018-2503-4
Soria F, Krabbe LM, Todenhöfer T, Dobruch J, Mitra AP, Inman BA et al. Molecular markers in bladder cancer. World Journal of Urology. 2018 Jan 1. https://doi.org/10.1007/s00345-018-2503-4
Soria, Francesco ; Krabbe, Laura Maria ; Todenhöfer, Tilman ; Dobruch, Jakub ; Mitra, Anirban P. ; Inman, Brant A. ; Gust, Kilian M. ; Lotan, Yair ; Shariat, Shahrokh F. / Molecular markers in bladder cancer. In: World Journal of Urology. 2018.
@article{51810c25ab6b4870ae2ffde07efce1e0,
title = "Molecular markers in bladder cancer",
abstract = "Purpose: Use of molecular markers in urine, tissue or blood offers potential opportunities to improve understanding of bladder cancer biology which may help identify disease earlier, risk stratify patients, improve prediction of outcomes or help target therapy. Methods: A review of the published literature was performed, without restriction of time. Results: Despite the fast-growing literature about the topic and the approval of several urinary biomarkers for use in clinical practice, they have not reached the level of evidence for widespread utilization. Biomarkers could be used in different clinical scenarios, mainly to overcome the limitations of current diagnostic, predictive, and prognostic tools. They have been evaluated to detect bladder cancer in asymptomatic populations or those with hematuria and in surveillance of disease as adjuncts to cystoscopy. There is also a potential role as prognosticators of disease recurrence, progression and survival both in patients with non-invasive cancers and in those with advanced disease. Finally, they promise to be helpful in predicting the response to local and/or systemic chemotherapy and/or immunotherapy. Conclusions: To date, due to the lack of high-quality prospective trials, the level of evidence provided by the current literature remains low and, therefore, the potential of biomarkers exceeds utilization in clinical practice.",
keywords = "Bladder cancer, Blood biomarkers, Guidelines, Tissue biomarkers, Urinary biomarkers",
author = "Francesco Soria and Krabbe, {Laura Maria} and Tilman Todenh{\"o}fer and Jakub Dobruch and Mitra, {Anirban P.} and Inman, {Brant A.} and Gust, {Kilian M.} and Yair Lotan and Shariat, {Shahrokh F.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00345-018-2503-4",
language = "English (US)",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Molecular markers in bladder cancer

AU - Soria, Francesco

AU - Krabbe, Laura Maria

AU - Todenhöfer, Tilman

AU - Dobruch, Jakub

AU - Mitra, Anirban P.

AU - Inman, Brant A.

AU - Gust, Kilian M.

AU - Lotan, Yair

AU - Shariat, Shahrokh F.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: Use of molecular markers in urine, tissue or blood offers potential opportunities to improve understanding of bladder cancer biology which may help identify disease earlier, risk stratify patients, improve prediction of outcomes or help target therapy. Methods: A review of the published literature was performed, without restriction of time. Results: Despite the fast-growing literature about the topic and the approval of several urinary biomarkers for use in clinical practice, they have not reached the level of evidence for widespread utilization. Biomarkers could be used in different clinical scenarios, mainly to overcome the limitations of current diagnostic, predictive, and prognostic tools. They have been evaluated to detect bladder cancer in asymptomatic populations or those with hematuria and in surveillance of disease as adjuncts to cystoscopy. There is also a potential role as prognosticators of disease recurrence, progression and survival both in patients with non-invasive cancers and in those with advanced disease. Finally, they promise to be helpful in predicting the response to local and/or systemic chemotherapy and/or immunotherapy. Conclusions: To date, due to the lack of high-quality prospective trials, the level of evidence provided by the current literature remains low and, therefore, the potential of biomarkers exceeds utilization in clinical practice.

AB - Purpose: Use of molecular markers in urine, tissue or blood offers potential opportunities to improve understanding of bladder cancer biology which may help identify disease earlier, risk stratify patients, improve prediction of outcomes or help target therapy. Methods: A review of the published literature was performed, without restriction of time. Results: Despite the fast-growing literature about the topic and the approval of several urinary biomarkers for use in clinical practice, they have not reached the level of evidence for widespread utilization. Biomarkers could be used in different clinical scenarios, mainly to overcome the limitations of current diagnostic, predictive, and prognostic tools. They have been evaluated to detect bladder cancer in asymptomatic populations or those with hematuria and in surveillance of disease as adjuncts to cystoscopy. There is also a potential role as prognosticators of disease recurrence, progression and survival both in patients with non-invasive cancers and in those with advanced disease. Finally, they promise to be helpful in predicting the response to local and/or systemic chemotherapy and/or immunotherapy. Conclusions: To date, due to the lack of high-quality prospective trials, the level of evidence provided by the current literature remains low and, therefore, the potential of biomarkers exceeds utilization in clinical practice.

KW - Bladder cancer

KW - Blood biomarkers

KW - Guidelines

KW - Tissue biomarkers

KW - Urinary biomarkers

UR - http://www.scopus.com/inward/record.url?scp=85053924541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053924541&partnerID=8YFLogxK

U2 - 10.1007/s00345-018-2503-4

DO - 10.1007/s00345-018-2503-4

M3 - Article

C2 - 30259123

AN - SCOPUS:85053924541

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

ER -